Specifically, our findings highlight a new approach to regulating SET expression via TRIM4‐induced K48‐linked polyubiquitination and proteasomal degradation of SET, thereby outlining a promising therapeutic target for the remediation of TAM resistance in ER‐α‐positive breast cancer and other diseases associated with aberrant SET expression. Here, ESR1 is linked to breast carcinoma.